Colleen Kusy
Stock Analyst at Baird
(1.82)
# 3,320
Out of 5,022 analysts
50
Total ratings
36.36%
Success rate
-8.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $11.85 | +102.53% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $2.00 | +350.00% | 1 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $47 → $50 | $24.14 | +107.13% | 12 | Jul 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $89.75 | +24.79% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $20.66 | +151.69% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.05 | +48.15% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $21.00 | +95.24% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.73 | +246.82% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $18.92 | +243.64% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $100 → $75 | $9.91 | +656.81% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $13.91 | +79.73% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $5.62 | +3,636.65% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.14 | +1,488.79% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.31 | +9,856.71% | 1 | Nov 2, 2021 |
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $11.85
Upside: +102.53%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $2.00
Upside: +350.00%
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47 → $50
Current: $24.14
Upside: +107.13%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $89.75
Upside: +24.79%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $20.66
Upside: +151.69%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.05
Upside: +48.15%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $21.00
Upside: +95.24%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.73
Upside: +246.82%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $18.92
Upside: +243.64%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $9.91
Upside: +656.81%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $13.91
Upside: +79.73%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $5.62
Upside: +3,636.65%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.14
Upside: +1,488.79%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.31
Upside: +9,856.71%